Skip to main content

Amylyx Pharmaceuticals, Inc.

AMLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001658551

In the last 90 days, Amylyx Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 206 institutions reported holding it in 13F filings for Q2 2026, worth $2.07B in total; no superinvestor holds it.

13F holders, Q4 2022

Institutional positions in Amylyx Pharmaceuticals, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
133
+39 vs. Q3 2022
Shares held
48.6M
+11.3M (+30.3%) vs. Q3 2022
Total value
$1.79B
+$748.1M (+71.6%) vs. Q3 2022
New holders
47
49 more added
Sold out
8
32 more reduced

1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q3 2022: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting AMLX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ4 2022: 133 institutions
Q1 2021: 0 institutionsQ2 2021: 0 institutionsQ3 2021: 0 institutionsQ4 2021: 0 institutionsQ1 2022: 72 institutionsQ2 2022: 78 institutionsQ3 2022: 95 institutionsQ4 2022: 133 institutionsQ1 2023: 147 institutionsQ2 2023: 154 institutionsQ3 2023: 170 institutionsQ4 2023: 178 institutionsQ1 2024: 143 institutionsQ2 2024: 119 institutionsQ3 2024: 110 institutionsQ4 2024: 122 institutionsQ1 2025: 136 institutionsQ2 2025: 131 institutionsQ3 2025: 169 institutionsQ4 2025: 180 institutionsQ1 2026: 171 institutionsQ2 2026: 206 institutions
Value heldQ4 2022: $1.79B
Q1 2021: $0Q2 2021: $0Q3 2021: $0Q4 2021: $0Q1 2022: $299.9MQ2 2022: $512.9MQ3 2022: $1.05BQ4 2022: $1.79BQ1 2023: $1.51BQ2 2023: $1.18BQ3 2023: $1.08BQ4 2023: $887.4MQ1 2024: $141.5MQ2 2024: $82.9MQ3 2024: $140.8MQ4 2024: $188.3MQ1 2025: $261.6MQ2 2025: $523.6MQ3 2025: $1.49BQ4 2025: $1.36BQ1 2026: $1.59BQ2 2026: $2.07B
Institutions holding AMLX and their total value by quarter
QuarterHoldersValue
Q2 2026206$2.07B
Q1 2026171$1.59B
Q4 2025180$1.36B
Q3 2025169$1.49B
Q2 2025131$523.6M
Q1 2025136$261.6M
Q4 2024122$188.3M
Q3 2024110$140.8M
Q2 2024119$82.9M
Q1 2024143$141.5M
Q4 2023178$887.4M
Q3 2023170$1.08B
Q2 2023154$1.18B
Q1 2023147$1.51B
Q4 2022133$1.79B
Q3 202295$1.05B
Q2 202278$512.9M
Q1 202272$299.9M
Q4 20210$0
Q3 20210$0
Q2 20210$0
Q1 20210$0

Institutions, Q4 2022

Shares, value and share of portfolio for each institution holding Amylyx Pharmaceuticals, Inc.; share changes are against Q3 2022.

Institutions holding AMLX in Q4 2022
InstitutionSharesValue% of portfolioChange in sharesAction
Iron Triangle Partners LP240,240$8.88M1.59%+240,240New
Eventide Asset Management, LLC250,000$9.24M0.18%+250,000New
Verition Fund Management LLC260,551$9.63M0.19%−51,865−16.6%Reduced
Allspring Global Investments Holdings, LLC266,019$9.83M0.02%−3,479−1.3%Reduced
Voloridge Investment Management, LLC295,267$10.9M0.06%−86,945−22.7%Reduced
Charles Schwab Investment Management Inc317,719$11.7M0.00%+76,980+32.0%Added
Ghost Tree Capital, LLC350,000$12.9M5.52%−200,000−36.4%Reduced
Northern Trust Corp395,139$14.6M0.00%+109,331+38.3%Added
Morgan Stanley484,469$17.9M0.00%+215,399+80.1%Added
Woodline Partners LP508,353$18.8M0.26%−512,031−50.2%Reduced
Cormorant Asset Management, LP550,000$20.3M1.37%−60,000−9.8%Reduced
Nuveen Asset Management, LLC596,054$22.0M0.01%+239,367+67.1%Added
Avoro Capital Advisors LLC630,000$23.3M0.35%−20,000−3.1%Reduced
Balyasny Asset Management LLC645,553$23.9M0.08%+454,219+237.4%Added
Emerald Mutual Fund Advisers Trust655,015$24.2M1.50%+183,128+38.8%Added
Falcon Edge Capital, LP821,220$30.3M5.54%+120,585+17.2%Added
Emerald Advisers, LLC836,909$30.9M1.49%+235,683+39.2%Added
Geode Capital Management, LLC853,913$31.6M0.00%+218,357+34.4%Added
Millennium Management LLC859,415$31.8M0.04%−61,713−6.7%Reduced
Goldman Sachs Group Inc1,036,270$38.3M0.01%+656,871+173.1%Added
State Street Corp1,075,612$39.7M0.00%+248,544+30.1%Added
Pictet Asset Management SA1,121,765$41.4M0.06%+1,121,765New
Rock Springs Capital Management LP1,229,637$45.4M1.09%+825,900+204.6%Added
D. E. Shaw & Co., Inc.1,383,732$51.1M0.09%+1,221,467+752.8%Added
Federated Hermes, Inc.1,614,845$59.7M0.17%+285,845+21.5%Added
Adage Capital Partners GP, L.L.C.1,909,201$70.5M0.17%+559,201+41.4%Added
Boxer Capital, LLC2,084,000$77.0M4.14%00.0%Unchanged
Point72 Asset Management, L.P.2,127,960$78.6M0.30%+1,660,999+355.7%Added
Deerfield Management Company, L.P. (Series C)2,693,000$99.5M2.06%+2,693,000New
BlackRock Inc.3,616,926$133.6M0.00%+1,321,092+57.5%Added
Vanguard Group Inc4,358,492$161.0M0.00%+844,136+24.0%Added
Viking Global Investors LPSuperinvestorViking Global Investors4,634,606$171.2M0.86%−1,135,930−19.7%Reduced
Perceptive Advisors LLC6,088,333$225.0M6.48%+616,300+11.3%Added
Bain Capital Life Sciences Investors, LLC0$00.00%−1,023,214−100.0%Sold out
Marshall Wace, LLP0$00.00%−341,064−100.0%Sold out
Pura Vida Investments, LLC0$00.00%−68,652−100.0%Sold out
Caption Management, LLC0$00.00%−42,947−100.0%Sold out
Susquehanna International Group, LLP0$00.00%−10,285−100.0%Sold out
Loring Wolcott & Coolidge Fiduciary Advisors LLP0$00.00%−1,803−100.0%Sold out
Cowen and Company, LLC0$00.00%−20,800−100.0%Sold out
Ronald Blue Trust, Inc.0$00.00%−15−100.0%Sold out
Jefferies Group LLC––––Not filed